COLORECTAL ADENOCARCINOMA WITH KRAS G12C MUTATION
Clinical trials for COLORECTAL ADENOCARCINOMA WITH KRAS G12C MUTATION explained in plain language.
Never miss a new study
Get alerted when new COLORECTAL ADENOCARCINOMA WITH KRAS G12C MUTATION trials appear
Sign up with your email to follow new studies for COLORECTAL ADENOCARCINOMA WITH KRAS G12C MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat cancers with KRAS mutation
Disease control Recruiting nowThis early-stage study is testing a new drug called calderasib (MK-1084) in people with advanced solid tumors that have a specific KRAS G12C mutation. The drug is given alone or combined with other cancer treatments. The main goals are to check safety and find the right dose. Abo…
Matched conditions: COLORECTAL ADENOCARCINOMA WITH KRAS G12C MUTATION
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests an experimental drug called KQB365 in adults with advanced solid tumors that have KRAS G12S or G12C mutations and haven't responded to standard treatments. The main goals are to find a safe dose and see if KQB365 alone or combined with other drugs can…
Matched conditions: COLORECTAL ADENOCARCINOMA WITH KRAS G12C MUTATION
Phase: PHASE1 • Sponsor: Kumquat Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC